Greg Weaver CFO Sirna therapeutics Greg Weaver, CFO, Sirna therapeutics Methods in Bioengineering: Nanoscale Bioengineering and Nanomedicine a book co-edited by Dr. Rege... Methods in Bioengineering: Nanoscale Bioengineering and Nanomedicine , a book co-edited by Dr. Rege... Title Nine campaign Title Nine campaign 12.01.2014 New Paper Documenting Alnylam’s Pioneering Discovery of GalNAc-Conjugated siRNA We have... 12.01.2014 New Paper Documenting Alnylam’s Pioneering Discovery of GalNAc-Conjugated siRNA We have... Greg Weaver CFO Sirna therapeutics Greg Weaver, CFO, Sirna therapeutics Title Nine campaign Title Nine campaign 07.22.2014 RNAi Roundtable: Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization... 07.22.2014 RNAi Roundtable: Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization... Shown are examples of chemical modifications of siRNA at the 2 Shown are examples of chemical modifications of siRNA at the 2 Figure 3 : PSMA aptamer Figure 3 : PSMA aptamer
Advanced Search